Blue Trust Inc’s ArriVent BioPharma AVBP Stock Holding History

Blue Trust Inc’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-39	Closed	-$723	–	3029
2024 Q3	$723	Buy	+39	New	+$885	﹤0.01%	2749

Other funds holding AVBP

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return

Blue Trust Inc's AVBP Position: Q4 2024 in Review

Blue Trust Inc sold out of ArriVent BioPharma (AVBP) in Q4 2024, closing a stake of 39 shares — an estimated $723 sold.

Blue Trust Inc first reported a position in AVBP in Q3 2024 and held it in 1 quarter. The position peaked at $723 in Q3 2024. 80 funds tracked by Wall St. Rank hold AVBP as of Q4 2024.

Blue Trust Inc reported no remaining ArriVent BioPharma position as of Q4 2024 after selling out during the quarter.
Blue Trust Inc sold 39 ArriVent BioPharma shares in Q4 2024, an estimated $723.
Blue Trust Inc first reported a position in ArriVent BioPharma in Q3 2024 and held it in 1 quarter.
Blue Trust Inc's ArriVent BioPharma position peaked at $723 in Q3 2024.
80 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q4 2024.

Based on Blue Trust Inc's 13F filing for Q4 2024, filed 22 Jan 2025.